Analyses define treatment outcomes in estrogen receptor low-positive metastatic breast cancer, suggesting endocrine therapy is beneficial.
PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.
No takes yet. Share an insight, caveat, or question.
Klugman et al. (2026) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: